Skip to NavigationSkip to content

Pharmafile - Research and Development

Roche's Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma
New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq  in combination with Avastin in the treatment of unresectable...
Top Ten most popular articles on Pharmafile.com this week
It’s time for a rundown of the top 10 articles on PharmaFile this past week. The past seven days saw the first and only transdermal patch for...
UCB's bimekizumab meets primary and secondary endpoints, beating Janssen's Stelara in chronic plaque psoriasis
UCB Pharma has announced new data from the first of three Phase 3 studies investigating the efficacy of its IL-17A and IL-17F inhibitor bimekizumab...
Ipsen acquires Blueprint drug and moves further into ultra-rare disease
Ipsen has announced that through its subsidiary Clementia Pharmaceuticals, it has entered into an exclusive, worldwide license agreement for the...
>> More Research and Development News Stories

Features

Medical cannabis: Growth by leaps and bounds

In June 2019, Pharmafocus visited the headquarters of cannabis company Canopy Growth in the Canadian town of Smiths Falls. Louis Goss...

>> More Features

Appointments

Gilead appoints Andrew Dickinson as CFO

Gilead Sciences have announced that Andrew Dickinson has been appointed as Chief Financial Officer (CFO) effective 1 November.

Dickinson...

For more appointments click here

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches